Novo Nordisk’s CFO on the oral Wegovy rollout and beyond

Novo Nordisk’s second-quarter earnings exceeded market expectations, prompting a significant increase in full-year guidance driven by robust volume growth in the GLP-1 franchise. CFO Karsten Munk Knudsen highlights that the European rollout of the oral Wegovy pill, particularly in the UK, is experiencing rapid uptake via telehealth platforms. Market data indicates that 80% of these users are new to the obesity category, limiting cannibalization of existing injectable products. Despite competitive pressures and patent expirations in markets like Canada and Brazil, the company remains optimistic about its pipeline, specifically the potential of CagriSema. Furthermore, aggressive cost-saving initiatives, including a reduction of 12,000 employees, have successfully freed up capital to prioritize R&D investments and sustain long-term innovation-based growth amidst ongoing shareholder scrutiny.